214 related articles for article (PubMed ID: 25793531)
1. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
Estill J; Egger M; Blaser N; Vizcaya LS; Garone D; Wood R; Campbell J; Hallett TB; Keiser O;
AIDS; 2013 Jun; 27(9):1483-92. PubMed ID: 23462219
[TBL] [Abstract][Full Text] [Related]
3. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
[TBL] [Abstract][Full Text] [Related]
6. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
8. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
9. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
[TBL] [Abstract][Full Text] [Related]
10. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.
Kahn JG; Marseille E; Moore D; Bunnell R; Were W; Degerman R; Tappero JW; Ekwaru P; Kaharuza F; Mermin J
BMJ; 2011 Nov; 343():d6884. PubMed ID: 22074713
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.
Phillips A; Cambiano V; Nakagawa F; Mabugu T; Miners A; Ford D; Pillay D; De Luca A; Lundgren J; Revill P
PLoS One; 2014; 9(10):e109148. PubMed ID: 25290340
[TBL] [Abstract][Full Text] [Related]
13. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
[TBL] [Abstract][Full Text] [Related]
14. Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis.
Negoescu DM; Zhang Z; Bucher HC; Bendavid E;
Clin Infect Dis; 2017 Jun; 64(12):1724-1730. PubMed ID: 28329208
[TBL] [Abstract][Full Text] [Related]
15. Field performance and cost-effectiveness of a point-of-care triage test for HIV virological failure in Southern Africa.
Saura-Lázaro A; Bock P; Bogaart EVD; van Vliet J; Granés L; Nel K; Naidoo V; Scheepers M; Saunders Y; Leal N; Ramponi F; Paulussen R; de Wit TR; Naniche D; López-Varela E
J Int AIDS Soc; 2023 Oct; 26(10):e26176. PubMed ID: 37803882
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.
Bendavid E; Young SD; Katzenstein DA; Bayoumi AM; Sanders GD; Owens DK
Arch Intern Med; 2008 Sep; 168(17):1910-8. PubMed ID: 18809819
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
18. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
[TBL] [Abstract][Full Text] [Related]
19. On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings.
Rutstein SE; Golin CE; Wheeler SB; Kamwendo D; Hosseinipour MC; Weinberger M; Miller WC; Biddle AK; Soko A; Mkandawire M; Mwenda R; Sarr A; Gupta S; Mataya R
AIDS Care; 2016; 28(1):1-10. PubMed ID: 26278724
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
Zang X; Tang H; Min JE; Gu D; Montaner JS; Wu Z; Nosyk B
PLoS One; 2016; 11(11):e0167308. PubMed ID: 27893864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
